39P Tissue vs. cobas vs. DDPCR for EGFR in NSCLC: Real-world evidence from India
نویسندگان
چکیده
منابع مشابه
Aggressive vs nonaggressive therapy for metastatic NSCLC.
Clinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related s...
متن کاملReal-World Decision Making: Logging Into Secure vs. Insecure Websites
A novel Two-Alternative Forced Choice experiment was used to evaluate the effects of security indicators on participants’ decision making when identifying potentially risky websites. Participants recruited from Amazons Mechanical Turk were instructed to visit a series of secure and insecure websites, and decide as quickly and as accurately as possible whether or not it was safe to login. Hierar...
متن کاملA Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR) T790M mutations from circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance would be desirable to direct patient sequential treatment strategy. A comparison of two platforms for detecting EGFR mutations in plasma ctDNA was undertaken. Plasma sa...
متن کاملTotal DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR
We evaluated the use of droplet digital PCR (ddPCR) to detect plasma cell-free DNA (cfDNA) epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC) patients. Compared with tumor-tissue-based detection, the sensitivity of ddPCR for detecting plasma cfDNA tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutations was 61.3%, the specificity was 96.7%, and th...
متن کاملSwitch Maintenance Tyrosine Kinase Inhibitors in EGFR Mutation Positive Metastatic Non-squamous NSCLC: Experience from the real world.
BACKGROUND Induction pemetrexed platin doublet is the standard of care in locally advanced and metastatic non squamous NSCLC. Maintenance TKI has been successfully explored to sustain benefit achieved after induction therapy especially in EGFR mutation positive NSCLC. The aim of this study is to evaluate outcomes with maintenance TKI in EGFR mutation positive metastatic non squamous NSCLC after...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: 1556-0864
DOI: 10.1016/s1556-0864(21)01881-5